+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
544694 NUTRA

Accretion Nutraveda Share Price

 

 

Accretion Nutraveda live price: ₹268.8. It opened at ₹269 vs previous close ₹259; intraday high/low: ₹269/₹269. The 50 DMA stands at ₹239.30.

Accretion Nutraveda Performance

  • Today's Low
  • ₹269
  • Today's High
  • ₹269
  • 52 Week Low
  • ₹150
  • 52 Week High
  • ₹300
  • Open Price₹269
  • Previous Close₹259
  • Volume1,000
  • 50 DMA₹239.30
  • 100 DMA-
  • 200 DMA-

Accretion Nutraveda Chart

Investment Returns

  • Over 1 Month + 2.79%
  • Over 3 Month + 35.42%

Smart Investing Starts Here Start SIP with Accretion Nutraveda for Steady Growth!

Invest Now

Accretion Nutraveda Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 38.4
  • PEG Ratio
  • -
  • Market Cap Cr
  • 195
  • P/B Ratio
  • 5.5
  • Average True Range
  • 11.07
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 7.83
  • RSI
  • 56.82
  • MFI
  • 56.95

Accretion Nutraveda Financials

Accretion Nutraveda Technicals

EMA & SMA

Current Price
₹268.80
+ 10 (3.86%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 11
  • 20 Day
  • ₹259.70
  • 50 Day
  • ₹239.30
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

268.8 Pivot Speed
  • R3 268.80
  • R2 268.80
  • R1 268.80
  • S1 268.80
  • S2 268.80
  • S3 268.80

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Accretion Nutraveda Limited operates in healthcare, offering ayurvedic, nutraceutical, and pharmaceutical products. With a presence in over 20 countries, it delivers tablets, capsules, syrups, oils, inhalers, and other dosage forms for preventive and therapeutic use.

Accretion Nutraveda Ltd has an operating revenue of Rs. 54.61 Cr. on a trailing 12-month basis. An annual revenue growth of 110% is outstanding, Pre-tax margin of 18% is great, ROE of 14% is good. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 21% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 69 which is a FAIR score but needs to improve its earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Accretion Nutraveda Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-08 Audited Results

Accretion Nutraveda Shareholding Pattern

73.48%
1.08%
14.18%
11.26%

Accretion Nutraveda FAQs

Accretion Nutraveda share price is ₹268 As on 30 June, 2026 | 23:26

The Market Cap of Accretion Nutraveda is ₹194.6 Cr As on 30 June, 2026 | 23:26

The P/E ratio of Accretion Nutraveda is 38.4 As on 30 June, 2026 | 23:26

The PB ratio of Accretion Nutraveda is 5.5 As on 30 June, 2026 | 23:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23